Evaluation of antimutagenic effect of todralazine in cultured lymphocytes

Mutagenesis

Volumn 15, Issue 2, 2000, Pages 137-141

  Gasiorowski, Kazimierz ^a   Brokos, Barbara ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIMUTAGENIC AGENT; BENZO[A]PYRENE; FREE RADICAL; HYDRALAZINE; MITOMYCIN C; PHORBOL 13 ACETATE 12 MYRISTATE; TIOGUANINE; TODRALAZINE;

ADULT; AMES TEST; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CYTOKINESIS; DRUG MECHANISM; DRUG STRUCTURE; GENOTOXICITY; GRANULOCYTE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; LYMPHOCYTE CULTURE; MALE; MICRONUCLEUS TEST; MUTAGENICITY; PRIORITY JOURNAL; SISTER CHROMATID EXCHANGE;

BACTERIA (MICROORGANISMS);

EID: 0034102570     PISSN: 02678357     EISSN: None     Source Type: Journal    
DOI: 10.1093/mutage/15.2.137     Document Type: Article

References (37)

1. Ames, B.N., Shigenaga, M.K. and Gold, L.S. (1993) DNA lesions, inducible DNA repair and cell division: three key factors in mutagenesis and carcinogenesis. Environ. Health Perspect., 101 (suppl. 5), 35-44.
2. Antoshina, M.N. and Poriadkova, N.A. (1978) A technique for differential staining of sister chromatids without using fluorochrome. Cytol. Genet., 4, 349-352.
3. Blumberg, P.M. (1988) Protein kinase C as the receptor for the phorbol ester tumor promoters: sixth Rhoads memorial award lecture. Cancer Res., 48, 1-8.
4. Cavalieri, E.L. and Rogan, E.G. (1992) The approach to understanding aromatic hydrocarbon carcinogenesis. The central role of radical cation in metabolic activation. Pharmacol. Ther., 55, 183-199.
5. Chlopkiewicz, B., Ejchart, A. and Marczewska, J. (1995a) Studies on the mechanism of mutagenicity and genotoxicity induced by dihydralazine. Acta Biochim. Pol., 42, 292-296.
6. Chlopkiewicz, B., Ejchart, A. and Marczewska, J. (1995b) Genetic effects of binazine (todralazine) and hydralazine in vitro and in vivo. Acta Pol. Pharmacol. Drug Res., 52, 31-33.
7. Cordell, J.L., Fallini, B., Erber, W.N., Ghosh, A.K., Abdulaziz, Z., MacDonald, S., Pulford, K.A.F., Stein, H. and Mason, D.Y. (1984) Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J. Histochem. Cytochem., 32, 219-229.
8. De Flora, S., Zanacchi, P., Bennicelli, C., Camoirano, A., Cavanna, M., Sciabà, L., Cajelli, E., Faggin, P. and Brambilla, G. (1982) In vivo and in vitro genotoxicity of three antihypertensive hydrazine derivatives thydralazine, dihydralazine and endralazine). Environ. Mutagen., 4, 605-619.
9. Dix, T.A. and Marnet, L.J. (1981) Free radical epoxidation of 7,8-dihydrobenzo(a)pyrene by hematin and polyunsaturated fatty acid hydroperoxides. J. Am. Chem. Soc., 103, 6744-6746.
10. English, D. and Anderson, B.R. (1974) Single-step separation of blood cells. Granulocytes and mononuclear leukocytes on discontinuous density gradient of ficoll-hypaque. J. Immunol. Methods, 5, 249-254.
11. Fenech, M. (1993) The cytokinesis-blocked micronucleus technique: a detailed description of the method and its application to genotoxicity studies in human populations. Mutat. Res., 285, 35-44.
12. Frenkel, K. (1992) Carcinogen-mediated oxidant formation and oxidative DNA damage. Pharmacol. Ther., 53, 127-166.
13. Gasiorowski, K., Szyba, K., Sawicka, J. and Gulanowski, B. (1993) Mutagenicity of B(a)P in the presence of some hydralazine derivatives. Pol. J. Occup. Med. Environ. Health, 6, 383-389.
14. Gasiorowski, K., Szyba, K. and Urban, J. (1994a) Todralazine influence upon the mutagenicity of some direct-and indirect-acting mutagens. Mutat. Res., 324, 133-137.
15. Gasiorowski, K., Gulanowski, B., Szyba, K. and Urban, J. (1994b) Study on the mechanisms of todralazine antimutagenic activity: the effect upon mutagenicity of daunorubicine. Int. J. Occup. Med. Environ. Health, 7, 371-378.
16. Gasiorowski, K., Szyba, K., Sawicka, J. and Gulanowski, B. (1995) Evaluation of the mechanisms of todralazine effect on mutagenicity of benzo(a)pyrene. Int. J. Occup. Med. Environ. Health, 8, 267-273.
17. Gasiorowski, K., Szyba, K., Woźniak, D. and Gulanowski, B. (1997) Inhibition of potassium dichromate mutagenicity by todralazine. Mutagenesis, 12, 411-415.
18. Goldstein, J.A. and Faletto, M.B. (1993) Advances in mechanisms of activation and deactivation of environmental chemicals. Environ. Health Perspect., 100, 169-176.
19. Guengerich, F.P. (1992) Metabolic activation of carcinogens. Pharmacol. Ther., 54, 17-61.
20. 1 arrest after DNA damage. Environ. Health Perspect., 101 (suppl. 5), 55-58.
21. Kazanietz, M.G., Wang, S., Milne, G.W., Lewin, N.E., Lin, H.L. and Blumberg, P.M. (1995) Residues in the second cysteine-rich region of protein kinase C delta relevant to phorbol ester binding as revealed by site-directed mutagenesis. J. Biol. Chem., 270, 21852-21859.
22. Lee, T.-K., Wiley, A.L., Means, J.A. and Biggs, L. (1994) Preservation of cytoplasm in the human lymphocyte micronucleus assay. Mutagenesis, 9, 559-562.
23. Li, Y. and Trush, M.A. (1994) Reactive oxygen-dependent DNA damage resulting from the oxidation of phenolic compounds by a copper-redox cycle mechanism. Cancer Res., 54 (suppl.), 1895-1898.
24. MacLeod, M.C., Evans, F.E., Lay, J., Chiarelli, P., Geacintov, N.E., Powell, K.L., Daylong, A., Luna, E. and Harvey, R.G. (1994) Identification of a novel, N7-deoxyguanosine adduct as the major DNA adduct formed by a nonbay-region diol epoxide of benzo(a)pyrene with low mutagenic potential. Biochemistry, 33, 2977-2987.
25. Magaud, J.P., Sargent, I. and Mason, D.Y. (1988) Detection of human white cell proliferative responses by immuno-enzymatic measurement of bromodeoxyuridine uptake. J. Immunol. Methods, 106, 95-100.
26. Marnett, L.J. (1987) Peroxyl free radicals: potential mediators of tumor initiation and promotion. Carcinogenesis, 8, 1365-1373.
27. Metcalf, J.A., Gallin, J.I., Nauseef, W.M. and Root, R.K. (1986) Nitroblue tetrazolium test. In Metcalf, J.A. (ed.), Laboratory Manual of Neutrophil Function. Raven Press, New York, NY, pp. 100-103.
28. Montero, R., Gosebatt, M.E., Herrerra, L.A., Rojas, E. and Ostrosky-Wegman, P. (1993) The HPRT short-term assay in monitoring individuals exposed to genotoxic agents. Environ. Health Perpsect., 101 (suppl. 3), 135-138.
29. Nesnow, S., Ross, J.A., Stoner, G.D. and Mass, M.J. (1995) Mechanistic linkage between DNA adducts, mutations in oncogenes and tumorigenesis of carcinogenic environmental polycyclic aromatic hydrocarbons in strain A/J mice. Toxicology, 105, 403-413.
30. Ostrosky-Wegman, P., Montero, R., De Nava, C.C., Tice, R.R. and Albertini, R. (1987) The use of bromodeoxyuridine labeling in the human lymphocyte HGPRT somatic mutation assay. Mutat. Res., 191, 211-214.
31. Perry, P. and Wolff, S. (1974) New Giemsa method for the differential staining of sister chromatids. Nature, 251, 156-159.
32. Tauber, A.I., Cox, J.A., Curnutte, J.T., Carrol, P.M., Nakakuma, H., Warren, B., Gilbert, H. and Blumberg, P.M. (1989) Activation of human neutrophil NADPH-oxidase in vitro by the catalytic fragment of protein kinase C. Biochem. Biophys. Res. Commun., 158, 884-890.
33. Tomatis, L. (1993) Cell proliferation and carcinogenesis: a brief history and current view based on a IARC Workshop Report. Environ. Health Perspect., 101 (suppl. 5), 149-152.
34. Troll, W. and Weisner, R. (1985) The role of oxygen free radicals as a possible mechanism of tumor promotion. Annu. Rev. Pharmacol. Toxicol., 25, 509-528.
35. Vanderlaan, M. and Thomas, C.B. (1985) Characterization of monoclonal antibodies to bromodeoxyuridine. Cytometry, 6, 501-505.
36. Weinstein, I.B. (1988) The origins of human cancer: molecular mechanisms of carcinogenesis and their implications for cancer prevention and treatment -Twenty-seventh G.H.A. Clowes Memorial Award lecture. Cancer Res., 48, 4135-4143.
37. Williams, G.M., Mauze, G., McQueen, C.A. and Shimada, T. (1980) Genotoxicity of the antihypertensive drugs hydralazine and dihydralazine. Science, 210, 329-330.